НовостиBenzingaStifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Benzinga 2026.11.10 14:20 (GMT+0) Открыть на Benzinga Другие новости